JP2014503191A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503191A5
JP2014503191A5 JP2013537894A JP2013537894A JP2014503191A5 JP 2014503191 A5 JP2014503191 A5 JP 2014503191A5 JP 2013537894 A JP2013537894 A JP 2013537894A JP 2013537894 A JP2013537894 A JP 2013537894A JP 2014503191 A5 JP2014503191 A5 JP 2014503191A5
Authority
JP
Japan
Prior art keywords
synuclein
disease
pharmaceutical composition
ice
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537894A
Other languages
English (en)
Japanese (ja)
Other versions
JP6006908B2 (ja
JP2014503191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059463 external-priority patent/WO2012061785A2/en
Publication of JP2014503191A publication Critical patent/JP2014503191A/ja
Publication of JP2014503191A5 publication Critical patent/JP2014503191A5/ja
Application granted granted Critical
Publication of JP6006908B2 publication Critical patent/JP6006908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537894A 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用 Expired - Fee Related JP6006908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41085210P 2010-11-05 2010-11-05
US41085610P 2010-11-05 2010-11-05
US61/410,856 2010-11-05
US61/410,852 2010-11-05
PCT/US2011/059463 WO2012061785A2 (en) 2010-11-05 2011-11-04 Ice inhibiting compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2014503191A JP2014503191A (ja) 2014-02-13
JP2014503191A5 true JP2014503191A5 (cg-RX-API-DMAC7.html) 2014-12-18
JP6006908B2 JP6006908B2 (ja) 2016-10-12

Family

ID=46024857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537894A Expired - Fee Related JP6006908B2 (ja) 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Country Status (4)

Country Link
US (3) US20140309172A1 (cg-RX-API-DMAC7.html)
EP (2) EP2635906A4 (cg-RX-API-DMAC7.html)
JP (2) JP6006908B2 (cg-RX-API-DMAC7.html)
WO (2) WO2012061786A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140309172A1 (en) * 2010-11-05 2014-10-16 Dagmar Ringe Ice inhibiting compounds and uses thereof
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
ES2950100T3 (es) 2016-12-23 2023-10-05 Casp Aid Inc Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
WO2019161302A1 (en) * 2018-02-16 2019-08-22 University Of Southern California Biomarkers for parkinson's disease
US12319929B2 (en) 2018-05-15 2025-06-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
CA2071674C (en) 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
WO1993005071A1 (en) 1991-08-30 1993-03-18 Sterling Winthrop Inc. INTERLEUKIN 1β PROTEASE AND INTERLEUKIN 1β PROTEASE INHIBITORS
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
EP0627926B1 (en) 1992-02-21 1998-08-05 Merck & Co., Inc. (a New Jersey corp.) PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
FR2698984B1 (fr) 1992-12-04 1995-01-06 Commissariat Energie Atomique Procédé et dispositif d'acquisition d'une image à trois dimensions d'un petit objet par palpage lumineux et moyen d'étalonnage pour la mise en Óoeuvre d'une telle acquisition.
CN1118458C (zh) 1994-03-31 2003-08-20 弗特克斯药品有限公司 作为白细胞介素抑制剂的嘧啶基衍生物
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
ATE310528T1 (de) 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
EP0932600B1 (en) 1996-10-11 2006-02-08 Warner-Lambert Company Llc Sulfonamide substituted aspartic acid interleukin-1beta converting enzyme inhibitors
EP0932598A1 (en) 1996-10-11 1999-08-04 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
ATE229935T1 (de) 1996-10-11 2003-01-15 Warner Lambert Co Sulfonamid-inhibitoren des interleukin-1-beta konvertierenden enzyms
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
JP2002509153A (ja) 1998-01-20 2002-03-26 ワーナー−ランバート・カンパニー インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
EP1076563B1 (en) 1998-03-16 2005-05-11 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
ATE410439T1 (de) 1998-03-19 2008-10-15 Vertex Pharma Caspase inhibitoren
JP2002513766A (ja) 1998-05-05 2002-05-14 ワーナー−ランバート・カンパニー インターロイキン−１β変換酵素のスクシンアミド阻害剤
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US6391575B1 (en) * 1999-03-05 2002-05-21 Idun Pharmaceuticals, Inc. Methods for detecting membrane derived caspase activity and modulators thereof
KR20010110667A (ko) 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
JP2002539193A (ja) 1999-03-16 2002-11-19 メルク フロスト カナダ アンド カンパニー カスパーゼ−３阻害薬としてのγ−ケト酸ジペプチド類
EP1177168B1 (en) 1999-04-09 2007-05-30 Cytovia, Inc. Caspase inhibitors and the use thereof
AU773317B2 (en) 1999-07-19 2004-05-20 Merck Canada Inc. Pyrazinones, compositions containing such compounds
PT1163208E (pt) 1999-08-06 2004-08-31 Vertex Pharma Inibidores de caspase e as suas utilizacoes
CA2383002A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2296742T3 (es) 2000-03-29 2008-05-01 Vertex Pharmaceuticals Incorporated Inhibidores de caspasa de tipo carbamato y sus usos.
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AP2002002407A0 (en) 2000-05-23 2002-03-31 Vertex Pharma Caspase inhibitors and uses thereof.
AU2001275279B2 (en) 2000-06-07 2007-01-04 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
JP2004509120A (ja) 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
ATE359274T1 (de) 2000-11-21 2007-05-15 Vertex Pharma Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung
WO2002085899A1 (en) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
US6875765B2 (en) 2001-05-10 2005-04-05 Warner-Lambert Company Arylsulfonamide ethers, and methods of use thereof
US7351702B2 (en) 2001-05-23 2008-04-01 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2005509028A (ja) 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
WO2003072528A2 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
EP1485107A1 (en) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
AU2003272189A1 (en) 2002-04-05 2004-01-19 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
RU2005102094A (ru) 2002-06-28 2006-02-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы каспазы и их применение
CA2511235A1 (en) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP4820291B2 (ja) * 2003-05-19 2011-11-24 エラン ファーマシューティカルズ，インコーポレイテッド レヴィー小体病におけるαシヌクレインの切断断片
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050202508A1 (en) 2003-11-12 2005-09-15 Pasinetti Guilio M. Biomarker for Parkinson's disease
US7868033B2 (en) 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
JP2008500374A (ja) 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド 自己炎症性疾患の処置のためのｉｃｅインヒビター
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
AU2006213829A1 (en) 2005-02-08 2006-08-17 The Scripps Research Institute Inhibitors of transthyretin amyloid fibril formation
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
US20100004277A1 (en) 2006-01-26 2010-01-07 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
JP2009526834A (ja) 2006-02-17 2009-07-23 ジョアン マクローリン， タンパク質凝集の疾患の治療のための組成物および方法
EP2074223A4 (en) 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120276019A1 (en) * 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
WO2010054127A1 (en) 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
BRPI0923157B1 (pt) * 2008-12-19 2021-12-28 University Of Zürich Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
US20130289022A1 (en) * 2010-11-05 2013-10-31 Brandeis University Tetrameric alpha-synuclein and use thereof
US20140309172A1 (en) 2010-11-05 2014-10-16 Dagmar Ringe Ice inhibiting compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2014503191A5 (cg-RX-API-DMAC7.html)
US12203943B2 (en) Biomarkers of fast progression of chronic kidney disease
Liu et al. VHH phage-based competitive real-time immuno-polymerase chain reaction for ultrasensitive detection of ochratoxin A in cereal
US9134326B2 (en) Biomarkers for liver fibrosis
US10942188B2 (en) Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of COPD
JP2007535930A5 (cg-RX-API-DMAC7.html)
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
BR112012030788B8 (pt) Anticorpo monoclonal, linhagem celular de hibridoma, e métodos para identificar a presença e para determinação quantitativa de uma enzima aad-12
JP2012515226A5 (cg-RX-API-DMAC7.html)
JP2015533788A5 (cg-RX-API-DMAC7.html)
EP3526605B1 (en) Method for the detection of apolipoprotein e4
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
WO2008008463A3 (en) METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ
CN105102985A (zh) 用于指导血压下降疗法的肾上腺髓质素
JP2010522875A5 (cg-RX-API-DMAC7.html)
US20230408521A1 (en) Gdf-15 as a diagnostic marker for melanoma
Matsui et al. Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products
WO2005109000A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
CA3199237A1 (en) Methods for identifying and treating antibody-mediated acquired primary or recurrent idiopathic nephrotic syndrome
JP2014518624A5 (cg-RX-API-DMAC7.html)
JP2014224759A5 (cg-RX-API-DMAC7.html)
JP2009507471A5 (cg-RX-API-DMAC7.html)
WO2012165926A3 (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
BRPI0606307A2 (pt) formas de fator xlla e métodos para determinar as referidas formas
CN104937419B (zh) 预测受试者患癌症的风险或诊断癌症的方法